Regeneron Pharmaceuticals (REGN) Competitors

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.

Do institutionals & insiders believe in AMGN or REGN?

76.5% of Amgen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.8% of Amgen shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor AMGN or REGN?

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than Amgen. MarketBeat recorded 61 mentions for Regeneron Pharmaceuticals and 42 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Regeneron Pharmaceuticals' score of 1.07 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	28 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	38 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer AMGN or REGN?

Regeneron Pharmaceuticals received 1 more outperform votes than Amgen when rated by MarketBeat users. However, 71.71% of users gave Amgen an outperform vote while only 66.95% of users gave Regeneron Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amgen	Outperform Votes 1559 71.71%	Underperform Votes 615 28.29%
Regeneron Pharmaceuticals	Outperform Votes 1560 66.95%	Underperform Votes 770 33.05%

Do analysts rate AMGN or REGN?

Amgen presently has a consensus price target of $309.22, indicating a potential upside of 13.81%. Regeneron Pharmaceuticals has a consensus price target of $890.60, indicating a potential upside of 48.17%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.38
Regeneron Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

Is AMGN or REGN a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.5%. Regeneron Pharmaceuticals pays an annual dividend of $3.52 per share and has a dividend yield of 0.6%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Regeneron Pharmaceuticals pays out 9.0% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has more volatility & risk, AMGN or REGN?

Amgen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Which has stronger valuation and earnings, AMGN or REGN?

Regeneron Pharmaceuticals has lower revenue, but higher earnings than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$34.13B	4.28	$4.09B	$10.96	24.79
Regeneron Pharmaceuticals	$14.09B	4.61	$4.41B	$39.28	15.30

Is AMGN or REGN more profitable?

Regeneron Pharmaceuticals has a net margin of 31.07% compared to Amgen's net margin of 12.24%. Amgen's return on equity of 176.32% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	12.24%	176.32%	11.71%
Regeneron Pharmaceuticals	31.07%	16.32%	12.76%

Summary

Regeneron Pharmaceuticals beats Amgen on 14 of the 22 factors compared between the two stocks.